Table 4 Prognostic factors to predict treatment response after topotecan and cyclophosphamide containing induction therapy (univariate analysis)
|  | Response ≥ 90% | Response < 90% | Crude OR (95% CI) | p-value |
|---|---|---|---|---|
Age | 3.5 ± 2.5 | 4.1 ± 2.6 | 1.09 (0.93–1.28) | 0.307 |
Gender | ||||
 Male | 28 (45.2) | 34 (54.8) | 1 |  |
 Female | 14 (31.1) | 31 (68.9) | 1.82 (0.82–4.08) | 0.140 |
Grade of differentiation | ||||
 Poorly differentiate & Undifferentiate | 26 (40.0) | 39 (60.0) | 1 |  |
 Differentiate | 3 (37.5) | 5 (62.5) | 1.11 (0.24–5.06) | 0.892 |
MYNC | ||||
 Non-amplified | 17 (43.6) | 22 (56.4) | 1 |  |
 Amplified | 3 (25.0) | 9 (75.0) | 2.32 (0.54–9.9) | 0.256 |
Shimada histology | ||||
 Favorable | 4 (44.4) | 5 (55.6) | 1 |  |
 Unfavorable | 10 (43.5) | 13 (56.5) | 1.04 (0.22–4.91) | 0.960 |
NSE | 314.1 ± 398.9 | 415.7 ± 420.6 | 1.00 (1.00–1.00) | 0.222 |
VMA | 45.3 ± 93.3 | 22.7 ± 33.1 | 0.99 (0.99–1.00) | 0.115 |
Health care system | ||||
 University-based | 37 (45.7) | 44 (54.3) | 1 |  |
 Community-based | 5 (19.2) | 21 (80.8) | 3.53 (1.21–10.28) | 0.021 |